ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
about
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesLooking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.Biosimilar infliximab use in paediatric IBD.Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseasesBiosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaA descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish populationPreparing for the incoming wave of biosimilars in oncology
P2860
Q33665611-0C89A532-FDF5-471F-A4FB-FBAE35601402Q38686396-8D98E5C2-D423-4C49-AB57-EEEB58C83FA5Q38699157-7679D898-5EEE-4866-85F0-774ECD3E7342Q38735477-5A8324D5-ACF6-439A-BA80-6DBF00F7A67CQ38824505-92EE2935-E3D6-4DE4-8B07-381B22808D56Q42332419-A33300D7-D4C6-423B-ACDF-B571C82FFBFEQ42360803-050D6CB6-06E8-4B9E-A347-52D20A35559AQ42701889-B9D73851-6BCE-4013-9965-C7D9D5FB12A8Q44581309-677356C3-74FF-46A8-B1C4-9C3D9BF80168Q47102118-9F7FEF31-8723-45A3-817D-6313AFE3F929Q47109861-8B098130-E307-4B0E-8149-239858581BA6Q47662808-DD581496-987F-4C21-9933-D77F2986A274Q47681638-14A30E6F-2FEC-4F66-BF71-42DF642EC4F1Q48092457-4A554E4C-0DE1-4A4B-84AA-D19B596B01DFQ48217871-2F9B2F22-7BA0-4720-9FBD-F2179BD20570Q50073683-E8BDF854-0D7C-46D3-9915-4CBEFC982799Q50108062-9D71DC41-DB00-467E-826C-5B43F15AAF41Q57167308-BE12CA03-4C8D-41A1-B23C-0530BE78CA6EQ57173064-F7B4953A-7EEF-4B62-B206-0ABA53E69AAAQ57484897-D71EAAB6-D9CC-4560-8856-9591B0FF97F4Q58762727-DF9E38CD-9E60-452B-A1B0-A2564EAD5143
P2860
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@en
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@nl
type
label
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@en
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@nl
prefLabel
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@en
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@nl
P2093
P2860
P50
P356
P1476
ECCO Position Statement on the ...... atory Bowel Disease-An Update.
@en
P2093
Gerassimos Mantzaris
Janneke van der Woude
Julian Panes
Karen Kemp
Marc Ferrante
Silvio Danese
P2860
P356
10.1093/ECCO-JCC/JJW198
P577
2016-12-07T00:00:00Z